Does POLATUZUMAB VEDOTIN Cause Second primary malignancy? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Second primary malignancy have been filed in association with POLATUZUMAB VEDOTIN (POLIVY). This represents 0.3% of all adverse event reports for POLATUZUMAB VEDOTIN.
16
Reports of Second primary malignancy with POLATUZUMAB VEDOTIN
0.3%
of all POLATUZUMAB VEDOTIN reports
4
Deaths
2
Hospitalizations
How Dangerous Is Second primary malignancy From POLATUZUMAB VEDOTIN?
Of the 16 reports, 4 (25.0%) resulted in death, 2 (12.5%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for POLATUZUMAB VEDOTIN. However, 16 reports have been filed with the FAERS database.
What Other Side Effects Does POLATUZUMAB VEDOTIN Cause?
Disease progression (1,131)
Off label use (692)
Anaemia (344)
Blood lactate dehydrogenase increased (307)
Drug ineffective (305)
Neutropenia (303)
Death (295)
Covid-19 (286)
Febrile neutropenia (286)
Pyrexia (285)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which POLATUZUMAB VEDOTIN Alternatives Have Lower Second primary malignancy Risk?
POLATUZUMAB VEDOTIN vs POLATUZUMAB VEDOTIN-PIIQ
POLATUZUMAB VEDOTIN vs POLIDOCANOL
POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL
POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL 3350
POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL 3350\POTASSIUM\SODIUM BICARBONATE\SODIUM